Nothing Special   »   [go: up one dir, main page]

BR112012018256A2 - - Google Patents

Info

Publication number
BR112012018256A2
BR112012018256A2 BR112012018256A BR112012018256A BR112012018256A2 BR 112012018256 A2 BR112012018256 A2 BR 112012018256A2 BR 112012018256 A BR112012018256 A BR 112012018256A BR 112012018256 A BR112012018256 A BR 112012018256A BR 112012018256 A2 BR112012018256 A2 BR 112012018256A2
Authority
BR
Brazil
Application number
BR112012018256A
Other versions
BR112012018256A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112012018256A2 publication Critical patent/BR112012018256A2/pt
Publication of BR112012018256A8 publication Critical patent/BR112012018256A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012018256A 2010-03-04 2011-03-03 método de tratamento de doença de parkinson BR112012018256A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31039810P 2010-03-04 2010-03-04
US41282110P 2010-11-12 2010-11-12
US201161438416P 2011-02-01 2011-02-01
PCT/FI2011/000013 WO2011107653A2 (en) 2010-03-04 2011-03-03 Method for treating parkinson's disease

Publications (2)

Publication Number Publication Date
BR112012018256A2 true BR112012018256A2 (pt) 2011-09-09
BR112012018256A8 BR112012018256A8 (pt) 2017-12-19

Family

ID=44065577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018256A BR112012018256A8 (pt) 2010-03-04 2011-03-03 método de tratamento de doença de parkinson

Country Status (15)

Country Link
US (4) US20130137729A1 (pt)
EP (1) EP2542220B1 (pt)
JP (2) JP5774610B2 (pt)
KR (1) KR101868326B1 (pt)
CN (1) CN102781424B (pt)
AU (1) AU2011222856B2 (pt)
BR (1) BR112012018256A8 (pt)
CA (1) CA2784819C (pt)
EA (1) EA026419B1 (pt)
ES (1) ES2614179T3 (pt)
HK (1) HK1177896A1 (pt)
IL (1) IL221744A (pt)
MX (1) MX336187B (pt)
WO (1) WO2011107653A2 (pt)
ZA (1) ZA201205836B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1907382B1 (en) 2005-07-26 2015-05-27 Bial-Portela & CA, S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
CN102015696A (zh) 2008-03-17 2011-04-13 比艾尔-坡特拉有限公司 5-[3-(2,5-二氯-4,6-二甲基-1-氧吡啶-3-基)-[1,2,4]噁二唑-5-基]-3-硝基苯-1,2-二醇的晶型
KR20120027197A (ko) 2009-04-01 2012-03-21 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
ES2614179T3 (es) * 2010-03-04 2017-05-30 Orion Corporation Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad de Parkinson
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
PT3604299T (pt) 2011-12-13 2023-10-31 Bial Portela & Ca Sa Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
ES2955693T3 (es) 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
US9642810B2 (en) 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
RU2017120184A (ru) * 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
JP2018528205A (ja) * 2015-08-27 2018-09-27 プレクストン・セラピューティクス・ソシエテ・アノニム レボドパ誘発性ジスキネジア療法のための脳透過性クロモンオキシム誘導体
KR20200136008A (ko) * 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
CN112741808B (zh) * 2019-10-29 2024-02-06 南京济群医药科技股份有限公司 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20230181493A1 (en) * 2020-04-10 2023-06-15 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR20240080457A (ko) * 2022-11-30 2024-06-07 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L‐ドーパ誘導体
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2005063696A2 (de) 2003-12-31 2005-07-14 Cilag Ag Neue kristalline formen von entacapone und deren herstellung
MXPA06014132A (es) 2004-06-04 2007-03-07 Xenoport Inc Profarmacos de levodopa y sus composiciones y usos.
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
SI1896006T1 (sl) * 2005-06-08 2010-02-26 Orion Corp Postopek za izdelavo granul, ki vsebujejo entakapon, za oralne odmerne oblike
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
EP1907382B1 (en) * 2005-07-26 2015-05-27 Bial-Portela & CA, S.A. Nitrocatechol derivatives as comt inhibitors
EP1959948B1 (en) 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
MX2010009043A (es) 2008-02-28 2010-10-25 Bial Portela & Ca Sa Composicion farmaceutica para farmacos poco solubles.
US9289392B2 (en) * 2008-08-22 2016-03-22 Wockhardt Ltd. Extended release pharmaceutical composition of entacapone or salts thereof
AU2009283814B2 (en) * 2008-08-22 2014-05-01 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
ES2614179T3 (es) * 2010-03-04 2017-05-30 Orion Corporation Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad de Parkinson
JP5551001B2 (ja) 2010-06-22 2014-07-16 株式会社Pfu 摩擦係数推定装置および摩擦係数推定方法
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Also Published As

Publication number Publication date
JP2013521263A (ja) 2013-06-10
CA2784819A1 (en) 2011-09-09
IL221744A (en) 2016-11-30
US20210085635A1 (en) 2021-03-25
EP2542220A2 (en) 2013-01-09
KR101868326B1 (ko) 2018-06-19
WO2011107653A3 (en) 2011-11-03
US11771675B2 (en) 2023-10-03
US10857120B2 (en) 2020-12-08
ES2614179T3 (es) 2017-05-30
HK1177896A1 (zh) 2013-08-30
JP5774610B2 (ja) 2015-09-09
WO2011107653A8 (en) 2012-08-02
CA2784819C (en) 2018-02-13
AU2011222856B2 (en) 2015-10-15
US20240050394A1 (en) 2024-02-15
WO2011107653A2 (en) 2011-09-09
EA026419B1 (ru) 2017-04-28
CN102781424A (zh) 2012-11-14
US20150150839A1 (en) 2015-06-04
MX2012010161A (es) 2012-10-03
CN102781424B (zh) 2016-03-30
MX336187B (es) 2016-01-07
AU2011222856A1 (en) 2012-07-26
EP2542220B1 (en) 2016-11-02
BR112012018256A8 (pt) 2017-12-19
JP2015180644A (ja) 2015-10-15
US20130137729A1 (en) 2013-05-30
ZA201205836B (en) 2014-01-29
KR20130006638A (ko) 2013-01-17
EA201290865A1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
BR112013008959A2 (pt)
BR112012031500A2 (pt)
BR112012029986A2 (pt)
BR112012030039A2 (pt)
BR112012028408A2 (pt)
BR112012026492A2 (pt)
BR112012027808A2 (pt)
BR112012024897A2 (pt)
BR112012019354A2 (pt)
BR112012025307A2 (pt)
BR112012002126A2 (pt)
BR112012026946A2 (pt)
BR112012017960A2 (pt)
BR112012025482A2 (pt)
BR112013006400A2 (pt)
BR112012031826A2 (pt)
BR112012028186A2 (pt)
BR112012025577A2 (pt)
BR112012023249A2 (pt)
BR112012016456A2 (pt)
BR112012018256A2 (pt)
BR112012027015A2 (pt)
BR112012025308A2 (pt)
BR112012027945A2 (pt)
BR112012024872A2 (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02/01/2019.

B350 Update of information on the portal [chapter 15.35 patent gazette]